2009-11-18

Safety and Efficacy of Testosterone Gel in the Treatment of Male Hypogonadism

Lakshman, Kishore M, Shehzad Basaria. "Safety and efficacy of testosterone gel in the treatment of male hypogonadism" Clinical Interventions in Aging 4:397-412. (2009)
https://hdl.handle.net/2144/2535

Boston University
Safety and efficacy of testosterone gel in the treatment of male hypogonadism

Kishore M Lakshman
Shehzad Basaria
Section of endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA

Abstract: Transdermal testosterone gels were first introduced in the US in 2000. Since then, they have emerged as a favorable mode of testosterone substitution. Serum testosterone levels reach a steady-state in the first 24 hours of application and remain in the normal range for the duration of the application. This pharmacokinetic profile is comparable to that of testosterone patch but superior to injectable testosterone esters that are associated with peaks and troughs with each dose. Testosterone gels are as efficacious as patches and injectable forms in their effects on sexual function and mood. Anticipated increases in prostate-specific antigen with testosterone therapy are not significantly different with testosterone gels, and the risk of polycythemia is lower than injectable modalities. Application site reactions, a major drawback of testosterone patches, occur less frequently with testosterone gels. However, inter-personal transfer is a concern if appropriate precautions are not taken. Superior tolerability and dose flexibility make testosterone gel highly desirable over other modalities of testosterone replacement. Androgel and Testim, the two currently available testosterone gel products in the US, have certain brand-specific properties that clinicians may consider prior to prescribing.

Keywords: testosterone gel, Androgel, Testim, hypogonadism

Physiology of hypothalamic–pituitary–gonadal axis

Testicular function is dependent on the hypothalamic secretion of gonadotropin-releasing hormone (GnRH) which in turn stimulates the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary to act on the testis. This results in spermatogenesis and testosterone production via stimulation of seminiferous tubules and Sertoli cells, and Leydig cells, respectively. Testosterone is secreted at adult levels during three periods of male life: transient surge during the first trimester of intrauterine life, perinatal surge during early neonatal life, and continually after puberty to maintain androgenization. Testosterone exerts negative feedback both at the level of the hypothalamus and the pituitary gland. Additionally, sertoli cells produce inhibin that exerts a negative feedback on FSH secretion.

Diagnosis of androgen deficiency

The estimates of the prevalence of androgen deficiency, defined solely in terms of serum testosterone concentrations below the lower limit of the normal range for healthy young men, vary greatly among different studies. Longitudinal data from the Massachusetts Male Aging Study (MMAS) indicate that the prevalence of symptomatic androgen deficiency (Total testosterone <300 ng/dL) in men aged between 40–69 years is between 6% and 12%.1 In the Baltimore Longitudinal Study of Aging (BLSA), the prevalence
of low total testosterone levels (testosterone <325 ng/dL) increased from relatively low levels for men aged less than 49 years to 12%, 19%, 28%, and 49% in men in their 50’s, 60’s, 70’s, and 80’s, respectively. Cross-sectional data from the Boston Area Community Health (BACH) Survey estimate the prevalence of symptomatic androgen deficiency (testosterone <300 ng/dL and free testosterone <5 ng/dL) to be 5.6% in men aged between 30 and 79 years.

Androgen deficiency is a clinical syndrome complex that comprises symptoms and signs in conjunction with biochemical evidence of testosterone deficiency. Several professional societies have published guidelines for the diagnosis and treatment of androgen deficiency. These include the American Association of Clinical Endocrinologists (AACE), the Endocrine Society, the International Society of Andrology (ISA), European Association of Urology (EAU), European Academy of Andrology (EAA), and the American Society of Andrology (ASA).

According to the Endocrine Society guidelines of 2006, diagnosis of androgen deficiency should be made only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. The diagnostic evaluation of men with androgen deficiency proceeds in three steps. The first step includes evaluation of general health, lifestyle, and the use of recreational drugs such as alcohol, marijuana, opiates, and cocaine, and exclusion of systemic illnesses or medications that might affect testicular function such as cimetidine, spironolactone, and glucocorticoids. The second step is the measurement of total testosterone level, preferably in the morning, using a reliable assay. If the total testosterone level is low, this should be confirmed by repeating the measurement of morning total testosterone and in some patients (eg, obese and elderly men) by calculation or measurement of free or bioavailable testosterone. The third step in the diagnostic evaluation is to determine whether androgen deficiency is the result of a primary testicular dysfunction or secondary to a hypothalamic or pituitary disorder. This is best accomplished by measurement of serum LH and FSH levels. Elevated LH and FSH levels in association with low testosterone levels indicate primary testicular failure, while low or inappropriately normal gonadotropins in association with low testosterone levels indicate either a hypothalamic–pituitary defect or a dual defect. Measurements of prolactin and iron studies are also important aspects of evaluation.

Several complexities render the application of these guidelines into clinical practice difficult. To start with, studies are also important aspects of evaluation.

History of testosterone therapy

The first historic evidence that testosterone contributed to virility came from the early experiment of Berthold in 1849 when he transplanted testes from roosters in the abdomen of capons (castrated roosters) and observed that animals with transplanted testes behaved like normal roosters. They were noted to fight among themselves and showed an inclination towards hens. He reported that “these animals remained male in regards to voice, reproduction instinct, and growth of comb and wattles.” Following Berthold’s observation, there were several experiments using testicular extracts. The best known are those by Brown–Sequard (1889), when he injected testicular extracts from testicles of dogs and guinea pigs on himself at the age of 72. He claimed “a remarkable return of physical strength and endurance, a rejuvenated bowel system, and enhanced mental capacity.” Vornoff transplanted testes from animals to humans in the 1930’s for the purpose of rejuvenation, but the effectiveness of his methods was refuted by the Royal Society of London. Further milestones in androgen replacement were made with...
the isolation of steroidal androgens by Butenandt (1931), extraction of testosterone in a crystalline form from bull testes by David and colleagues (1935), and the chemical synthesis of testosterone by Butenandt and Hanish (1935), and Rizica and Wettstein (1935). Since testosterone per se was ineffective orally due to high first-pass metabolism in the liver, the initial forms of replacement was its alkylated form: 17α-methyl testosterone. Alternatively, testosterone was compressed into pellets and implanted subcutaneously. The era of longer acting injectable testosterone esters began in the 1950’s and quickly became the preferred modality of replacement. In the late 1970’s, the orally effective testosterone undecanoate became available. In the mid 1990’s, transdermal testosterone patches became available. These were applied either to the scrotal or nonscrotal skin. In 2000, the first transdermal testosterone gel (Androgel) became available for androgen replacement, initially in the US, and subsequently in other countries. In 2004, an injectable form of testosterone undecanoate that demonstrated a superior pharmacokinetic profile to other injectable preparations became available in Europe. Testosterone undecanoate is currently undergoing clinical trials in the United States. In this paper, we will only review the safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Testosterone gel

The need for a transdermal testosterone gel arose to overcome the drawbacks of the other delivery systems. For instance, injectable esters were associated with peaks and troughs of serum testosterone outside the physiological range, patches were associated with a high incidence of application site reactions, and pellets were associated with the risk of extrusion and infection.

The two commercially available forms of testosterone gel in the US are Androgel and Testim (1%) gels. Inactive ingredients in AndroGel are carboxer 980, ethanol (67.0%), isopropyl myristate, purified water, and sodium hydroxide. Inactive ingredients in Testim are purified water, pentadecalactone, carbopol, acrylates, propylene glycol, glycerin, polyethylene glycol, ethanol (74%), and tromethamine. Androgel is available in metered-dose pumps and packets. The metered-dose pump delivers 1.25 g of testosterone when the lever is fully depressed once. AndroGel packets are available in 2.5 g and 5 g dosing options. Testim gel is available as a single dose (tube) containing 5 g of the product.

The recommended starting dose of testosterone gel is 5 g/day and this provides a nominal delivery of 5 mg/day (1%) of testosterone systemically. Serum testosterone levels should be monitored serially to ensure proper dosing. If serum testosterone concentration is below the normal range or if the desired clinical response is not achieved, the dose may be increased from 5 g to 7.5–10 g. It is recommended that testosterone gel be applied early morning on intact dry skin over the shoulders, upper arms or in case of Androgel, the abdomen as well. Patients are advised to wash their hands well after application, allow the application site to dry for a few minutes and to cover the site with clothing. It is recommended to wait for four hours prior to showering or swimming. Application sites must be washed with soap and water if skin-to-skin contact of these areas is anticipated with another person.

Pharmacokinetics of testosterone gel

When an open system of hydroalcoholic gel of a steroid is applied to the skin, the steroid is rapidly absorbed into the stratum corneum, which forms a reservoir and acts as a rate-controlling membrane. The steroid then gradually diffuses from this skin reservoir over several hours, reaching steady-state levels in the serum. In 2000, AndroGel became available for treatment of male hypogonadism in the US. Wang and colleagues demonstrated that application of 10 g/day of AndroGel (applied either entirely at one site or at four different sites) resulted in a significant increase in serum testosterone levels with parallel and appropriate increases in serum dihydrotestosterone (DHT) and estradiol (E,) levels. After the first application of AndroGel to hypogonadal men, serum testosterone levels rose into the normal range within 30 min followed by a gradual rise throughout the following 24 hours (Figure 1). By the end of 1st day, the levels attained were comparable with the subsequent steady-state pre-dose levels on the 3rd, 5th, and 7th days of application. Mean serum testosterone levels were four- to fivefold above the baseline levels and at the upper limit of the normal range for the duration of gel application (one site: 745.53 ± 149.57 ng/dL; four sites: 794.52 ± 118.16), and returned to baseline within four days after stopping application. These serum patterns were similar, irrespective of the number of sites of application. However, the application of testosterone gel at four sites resulted in an area under the curve of testosterone, which was higher compared to application of the same amount of gel at one site (although this difference did not achieve statistical significance). Swerdloff and colleagues demonstrated long-term pharmacokinetics of 1% AndroGel in 227 hypogonadal men. Subjects were assigned randomly to receive 5 or 10 g of AndroGel or two nonscrotal patches. After 90 days of gel treatment, the dose was titrated up.
(5 to 7.5 g) or down (10 to 7.5 g) if the serum testosterone levels were outside the normal range. On repeated application, mean serum levels of testosterone were maintained in the middle normal range with 5 g gel and in the upper normal range with the 10 g gel. Pharmacokinetics on days 30, 90, and 180 remained remarkably similar and steady levels of serum testosterone were maintained. On longer follow up of up to 32 months, serum concentrations of total testosterone and free testosterone increased dose dependently in the first 12 months; thereafter, testosterone levels did not appear to be different26 (Figure 2).

In 2003, McNicholas and colleagues27 compared the response of two doses of 1% Testim (5 or 10 g/day) to 5 mg/day of Androderm patch in 208 hypogonadal men. Consistently throughout the study, Testim 10 g/day increased average, minimum, and maximum concentrations (Cavg, Cmin, and Cmax) more than both 5 g/day dose and Andropatch. At 90 days, the mean change from baseline with 10 g/day Testim was over three times greater than that with Andropatch (P < 0.001) and about twice as high as the 5 g/day Testim (P < 0.05). The results at 30 and 60 days were consistent with those at 90 days. The dose-dependent improvements in all pharmacokinetic profiles of testosterone gel in comparison to testosterone patch have been replicated in other studies.28–31

In a open-label crossover study of 30 hypogonadal men with human immunodeficiency virus (HIV), Scott and colleagues32 compared the response between weekly intramuscular (IM) testosterone (100–200 mg/week) and 1% Androgel (5–10 g/day) for eight weeks. Peak levels of serum-free testosterone concentrations were significantly greater after IM testosterone (42 pg/mL) than after Androgel (23 pg/mL) (P < 0.001). In addition, the peak-trough fluctuation in free testosterone was significantly greater after IM (26.7 ± 12.8 pg/mL) than Androgel (2.7 ± 10.2 pg/mL; P < 0.001). The percentage of patients who achieved therapeutic serum concentrations was 50% during IM and 83% during Androgel therapy.

A randomized, crossover study was performed by Marbury and colleagues33 to compare the pharmacokinetic profiles of Testim and Androgel. Twenty-nine hypogonadal subjects received a single dose (5 g) of each formulation seven days apart. Cmax estimates for total testosterone, free testosterone, and dihydrotestosterone were greater (30%, 38%, and 19%, respectively) following the application of Testim compared to Androgel. Similarly, area under the curve (AUC; 0–24) estimates for total testosterone, free testosterone, and dihydrotestosterone were greater (30%, 47%, and 11%, respectively) following the application of Testim compared to Androgel.

In summary, the pharmacokinetic profile and the dose proportionality observed after testosterone gel application indicate that this transdermal delivery system raises serum testosterone levels into mid-high normal adult male range in a uniform and predictable manner. However, since inter- and intraindividual variations exist, it is prudent to monitor serum testosterone levels serially.
Therapeutic efficacy

The effects of testosterone gel on outcomes such as body composition, bone mineral density (BMD), sexual function, and cognition have been studied in several intervention trials (Table 1).

Body composition

The mechanisms by which hormones influence body composition, muscle strength, and physical performance are only partly understood. Possible biological mechanisms include the effects of testosterone on regulation of mesenchymal stem cell differentiation and muscle protein synthesis through androgen receptor-mediated pathways. Testosterone could also indirectly affect body composition through its effects on various inflammatory pathways.

Wang and colleagues showed that after 90 days of treatment with 1% Androgel (5 or 10 g/day) or Androderm (5 mg/day), lean body mass (LBM) increased in all groups. However, the highest gains were seen in the 10 g/day group. Furthermore, reduction in fat mass (FM) and percent fat was only seen in the testosterone gel groups. On day 180, the changes in LBM and FM were maintained in the gel and patch groups. Similar changes in LBM and FM have been replicated in subsequent studies using 1% Testim. In an extension of their former study, Wang and colleagues followed hypogonadal patients receiving Androgel (5, 7.5, or 10 g/day) for an additional three years, and showed that LBM increased significantly from baseline and was maintained throughout the study period. The change in LBM was 1.97 ± 0.24 kg at six months, which increased to 2.93 ± 0.32 kg at 18 months and 2.89 ± 0.41 kg at 30 months ($P = 0.0065$). There was a concomitant decrease in FM. The decrease in FM was 0.8 ± 0.3 kg at six months, 1.57 ± 0.38 at 18 months, and 1.30 ± 0.51 kg at 30 months. However, neither LBM nor FM change was significantly different among the different dose groups nor was there a significant increase in muscle strength (Figure 3).

Bone density

Testosterone may also directly affect bone tissue. Androgen receptors have been identified on both the osteoblastic and osteoclastic lineages as well as chondrocytes. Androgens...
Urine N-telopeptide/creatinine ratio, a marker for bone resorption,
did not decrease during the study period.

Both doses of Testim significantly improved positive and negative mood
over baseline; Androderm did not. All three treatments increased
lean body mass, and the higher dose of Testim produced a significant
decrease in percentage body fat (−0.12%, P = 0.0019) only in the T gel 100 mg/day
treatment group. At all sample times both doses of Testim significantly improved sexual performance, sexual
motivation, sexual desire and spontaneous erections. Androderm provided
insignificant improvements from baseline at all sample times for sexual
desire, an inconsistent improvement in sexual motivation, but no effect
on spontaneous erections.

At day 90, the 100 mg/day Testim treatment improved lean body mass by
1.7 kg and percentage of body fat by 1.2% to a significantly greater degree
than either control treatment. Reductions in fat mass of 0.8 ± 0.4, 0.8 ± 2.0,
0.4 ± 1.8, and 1.0 ± 1.5 kg were noted in the 50 mg/day Testim gel, 100 mg/d
Testim gel, Androderm patch, and placebo treatment groups, respectively.

Significant improvements in spontaneous erections, sexual desire, and sexual motivation were
also evidenced with the 100 mg/d Testim dose in comparison with placebo
treatments yielding the most notable decreases. The 100 mg/day Testim
treatment resulted in a 1.2 ± 1.9% reduction at day 90, which was not only
significant in comparison with placebo (P = 0.01) but also significant in comparison
with the T patch treatment (0.5 ± 1.6%, P 0.05). Significant improve-
mantle

Table 1. Summary of efficacy data from testosterone trials using T gel in hypogonadal men

| First author, Ref | Patient details | Blinding | Control group | Regimen | Duration | Results |
|-------------------|-----------------|----------|---------------|---------|----------|---------|
| Wang et al21       | 227 hypogonadal men aged 19–68 years (Total T < 10.4 nmol/L) | Androgel treatments were double-blinded but Androderm was open-labeled | None | Randomized to receive –
  a. 1% Androgel (5 g/day) + placebo (1 + 1 pump)
  b. 1% Androgel (10 g/day) (2 pumps) or
  c. Andropatch (5 mg/day).
  Androgel doses were adjusted in future visits based on T levels and clinical symptoms | 180 days | At 90 days of treatment, lean body mass increased more in the 100 mg/day T gel group (2.74 ± 0.28 kg; P = 0.0002) than in the 50 mg/day T gel (1.28 ± 0.32 kg) and T patch groups (1.20 ± 0.26 kg). Fat mass and percent fat were not significantly decreased in the T patch group, but showed decreases in the T gel groups (50 mg/day, −0.90 ± 0.32 kg; 100 mg/day, −1.05 ± 0.22 kg). Sexual function and mood improved maximally on day 30 of treatment, without differences across groups, and showed no further improvement with continuation of treatment. Mean muscle strength in the leg press exercise increased by 11 to 13 kg in all treatment groups by 90 days and did not improve further at 180 days of treatment. Moderate increases were also observed in arm/chest muscle strength. Urine N-telopeptide/creatinine ratio, a marker for bone resorption, decreased significantly (P = 0.0019) only in the T gel 100 mg/day treatment. Serum bone osteoblastic activity markers (osteocalcin, procollagen and skeletal alkaline phosphatase) increased significantly during the first 90 days of treatment without intergroup differences but declined to baseline thereafter. BMD increased significantly both in the hip (+1.1 ± 0.3%) and spine (+2.2 ± 0.5%) only in the T gel 100 mg/day group (P = 0.0001). |
| Wang et al21       | 227 hypogonadal men aged 19–68 years (Total T < 10.4 nmol/L) | Androgel treatments were double-blinded but Androderm was open-labeled | None | Randomized to receive –
  a. 1% Androgel (5 g/day) + placebo (1 + 1 pump)
  b. 1% Androgel (10 g/day) (2 pumps) or
  c. Andropatch (5 mg/day).
  Androgel doses were adjusted in future visits based on T levels and clinical symptoms | 180 days | Both doses of Testim significantly improved positive and negative mood over baseline; Androderm did not. All three treatments increased lean body mass, and the higher dose of Testim produced a significant decrease in percentage body fat (−0.12%, P < 0.01). At all sample times both doses of Testim significantly improved sexual performance, sexual motivation, sexual desire and spontaneous erections. Androderm provided insignificant improvements from baseline at all sample times for sexual desire, an inconsistent improvement in sexual motivation, but no effect on spontaneous erections. |
| McNicholas et al27 | 208 hypogonadal men aged 31–80 years (Total T < 10.4 nmol/L) | Testim treatments were double-blinded but Androderm was open-labeled | None | Randomized to receive –
  a. 1% Testim (5 mg/day) or
  b. 1% Testim (10 mg/day) or
  c. Matching placebo gel or
  d. Androderm (5 mg/day) | 90 days | Both doses of Testim significantly improved positive and negative mood over baseline; Androderm did not. All three treatments increased lean body mass, and the higher dose of Testim produced a significant decrease in percentage body fat (−0.12%, P < 0.01). At all sample times both doses of Testim significantly improved sexual performance, sexual motivation, sexual desire and spontaneous erections. Androderm provided insignificant improvements from baseline at all sample times for sexual desire, an inconsistent improvement in sexual motivation, but no effect on spontaneous erections. |
| Steidle et al29    | 406 hypogonadal men aged 20–80 years (Total T < 10.4 nmol/L) | Testim treatments were double-blinded but Androderm was open-labeled | Placebo | Randomized to receive –
  a. 1% Testim (5 g/day) or
  b. 1% Testim (10 g/day) or
  c. Matching placebo gel or
  d. Androderm (5 mg/day) | 90 days | At day 90, the 100 mg/day Testim treatment improved lean body mass by 1.7 kg and percentage of body fat by 1.2% to a significantly greater degree than either control treatment. Reductions in fat mass of 0.8 ± 2.4, 0.8 ± 2.0, 0.4 ± 1.8, and 0.1 ± 1.5 kg were noted in the 50 mg/day Testim gel, 100 mg/d Testim gel, Androderm patch, and placebo treatment groups, respectively. Reductions in % fat were evidenced in all treatment groups, with the Testim treatments yielding the most notable decreases. The 100 mg/day Testim treatment resulted in a 1.2 ± 1.9% reduction at day 90, which was not only significant in comparison with placebo (P = 0.01) but also significant in comparison with the T patch treatment (0.5 ± 1.6%, P 0.05). Significant improvements in spontaneous erections, sexual desire, and sexual motivation were also evidenced with the 100 mg/d Testim dose in comparison with placebo treatments yielding the most notable decreases. The 100 mg/day Testim treatment resulted in a 1.2 ± 1.9% reduction at day 90, which was not only significant in comparison with placebo (P = 0.01) but also significant in comparison with the T patch treatment (0.5 ± 1.6%, P 0.05). Significant improvements in spontaneous erections, sexual desire, and sexual motivation were also evidenced with the 100 mg/d Testim dose in comparison with placebo.
| Study            | Participants                                                                 | Design                                      | Intervention                                                                 | Duration | Changes in Sexual Function Inventory                                                                 |
|------------------|------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------|
| Loizides et al.  | 638 hypogonadal men aged 18–86 (T < 300 ng/dL)                               | Open                                        | Single group study receiving 1% Testim (50 mg/day) and could increase up to 100 mg/day at the discretion of the investigator | 30 days  | Average score for sexual desire, sexual motivation, spontaneous erections (daytime and nighttime), sexual performance, sexual enjoyment, and satisfaction showed a significant increase from baseline by the end of the first week and generally reached a maximal response by the end of the second week, which was maintained for the remainder of the month of therapy with Testim. Both measures of positive mood and negative mood improved significantly, beginning with the first week of therapy and reaching and maintaining a maximal response at the second week. |
| Dean et al.      | 371 hypogonadal men aged 21–81 (Total T < 300 ng/dL) were recruited from those who had completed two short-term double-blind studies with Testim | Open                                        | Single group study receiving 1% Testim (5 g/day) and could increase up to 100 mg/day based on serum T levels and clinical symptoms | 12 months| Testim treatment resulted in significant changes in body composition at months 6 and 12 (Figures 5–7). These changes included significant increases in lean body mass (1.7 kg [month 6] and 2.2 kg [month 12]), significant decreases in fat mass (1.2 kg [month 6] and 1.8 kg [month 12]), and % fat (1.4% [month 6], and 2.1% [month 12]) but with no significant change in total body mass. Long-term treatment with Testim resulted in a significant (P < 0.001) percent change increase from baseline in BMD of the lumbar spine as measured by DEXA scan, reaching 2.58% at month 12. In addition, significant improvements in mood and sexual function were maintained for up to 12 months of treatment. |
| Wang et al.      | 163 hypogonadal men (mean age 51.4 yrs) were recruited from those who were in the six-month study using Androgel or Androderm to continue for an additional 36 months | Open                                        | Those who were receiving 5 g/day or 10 g/day of Androgel continued in the same group. Men receiving Androderm were assigned to Androgel, 5 g/day. Dose were adjusted in future visits based on T levels and clinical symptoms | 42 months| Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. |
| Steidle et al.   | 151 hypogonadal men (Total T < 10.4 nmol/L pre-treatment) who failed to experience satisfactory symptom relief of sexual dysfunction after treatment with Androgel | Androgel 5 g/day                             | Testim 5 g/day (treatment group) or Androgel 5 gm/day (control group)         | 4 weeks  | Changes from baseline in the 5 domains of the Brief Male Sexual Function Inventory were compared between groups. The mean percentage improvement favored Testim treatment in sexual drive (23% vs 16%, P < 0.3), erectile function (32% vs 8%, P < 0.03), ejaculatory function (11% vs 9%, P < 0.4), problem assessment (47% vs 12%, P < 0.01), and sexual satisfaction (62% vs 23%, P < 0.02). A greater percentage of subjects also reported satisfaction with the experimental treatment (55% vs 33%, P < 0.02), and these subjects were less likely to require upward dose titration at the final follow-up visit (53% vs 72%, P < 0.03). |
| Kuhnert et al.   | 162 hypogonadal men over 18 years (TotalT < 10 nmol/L)                       | Open                                        | Randomized to receive a. 1 g/day of 2.5% T gel (Testocur) applied to scrotal skin or b. 5 g/day to nonscrotal skin or c. 5 mg Androderm patch applied to nonscrotal skin daily | 24 weeks | Whereas serum testosterone levels and the pre-post changes of the areas under the curve of testosterone and free testosterone between weeks 0 and 24 indicated equivalent treatment success for the patch and scrotal groups, the dermal gel group was significantly superior to the other two groups. |

(Continued)
| First author, Ref | Patient details | Blinding | Control group | Regimen | Duration | Results |
|-------------------|----------------|----------|---------------|---------|----------|---------|
| Schrader et al⁵¹ | 48 HIV-positive hypogonadal males who failed to experience satisfactory symptom relief following prior treatment with Androgel 1% | Open | Androgel 5 g/day (treatment group) or Androgel 5 gm/day (control group) | 4 weeks | The average percentage improvement favored the experimental treatment in all five comparisons of the BMSFI, including sexual drive (53% vs 18%, P < 0.001), erectile function (49% vs 7%, P < 0.004), ejaculatory function (15% vs 8%, P < 0.14), problem assessment (59% vs 12%, P < 0.003), and sexual satisfaction (58% vs 9%, P < 0.006). A greater percentage of subjects also reported satisfaction with the experimental treatment (85% vs 48%, P < 0.03), and these subjects were less likely to require upward dose titration at the final follow-up visit (30% vs 74%, P = 0.01) |
| Scott et al⁵² | 30 HIV-positive hypogonadal males over aged 31–66 years who were already receiving IM testosterone with T levels in the eugonadal range | Open | Internal cross-over | IM Testosterone cypionate 100–200 mg every 1–2 weeks 1% Androgel 5 g/day. Both doses were adjusted in future visits based on T levels and clinical symptoms | 16 weeks | Mean peak free testosterone concentrations with IM testosterone and T gel were 42 pg/mL and 23 pg/mL, respectively, and mean peak trough fluctuations in free testosterone were 26.7 ± 12.8 pg/mL and 2.7 ± 10.7 pg/mL, respectively (P < 0.001). Quality-of-life scores indicated more improved physical and emotional well-being with gel versus intramuscular testosterone. No significant changes in laboratory parameters or lean body mass were noted |
| Shabsigh et al⁵⁷ | 75 hypogonadal men aged 17–80 years (TT < 400 ng/dL) with confirmed lack of response to ED to sildenafil | Double-blind | Placebo | 5 g/day of 1% Androgel or placebo gel + 100 mg of sildenafil/day | 12 weeks | Androgel treated subjects had greater improvement in erectile function compared to those who received placebo, reaching statistical significance at week 4 (4.4 vs 2.1, P = 0.029, 95.1% CI: 0.3, 4.7). Similar trends were observed for improvements in orgasmic function, overall satisfaction, total IIEF score and percentage of IIEF responders. T-gel significantly (P = 0.004) increased total and free T levels throughout the study, although no significant correlations were made between testosterone levels and the IIEF at end point. Mean total QOL scores were similar between groups at baseline. Throughout the study changes in QOL were generally small but were consistently better in subjects who received Tgel versus placebo reaching significance at week 12 (P = 0.028) 95.1% CI: 0.0, 0.5) and approaching significance at end point |

**Abbreviations:** CI, confidence interval; T, Testosterone; IIEF, International Index of Erectile Function; QOL, Quality of life; BMSFI, Brief Male Sexual Function Inventory; BMD, Bone Mineral Density; IM, Intramuscular.
exert proapoptotic effects on osteoclasts and antiapoptotic effects on osteoblasts and osteocytes. Testosterone also modulates the effects induced by other hormones and cytokines involved in bone metabolism.\textsuperscript{46} Testosterone exerts its influence on the (RANK)/osteoprotegerin (OPG) system\textsuperscript{47} and helps protect excessive bone resorption.\textsuperscript{48} Additionally, testosterone appears to indirectly limit bone resorption by inhibiting the expression of interleukins 1 and 6 and cytokines that induce bone resorption by promoting osteoclast activation and differentiation. Effects of testosterone on bone are also mediated via its conversion to estradiol.\textsuperscript{51} One recent study did not show adverse skeletal consequences by inhibiting aromatase by anastrazole.\textsuperscript{51}

A number of randomized placebo-controlled trials, both short-term and long-term, of testosterone therapy on bone outcomes have been conducted. In a three-month study of testosterone replacement with Testim,\textsuperscript{27} no significant BMD changes were observed, which confirms that a longer duration of treatment is needed to see considerable changes in BMD. Androgel application for six months was shown to decrease bone resorption markers and increase osteoblastic activity, resulting in a significant increase in BMD at the hip and spine.\textsuperscript{52} In the three-year extension of this study,\textsuperscript{26} bone turnover markers confirmed that in the early phase there was a decrease in bone resorption and an increase in bone formation. However, in the later phase there was no further decrease in bone resorption. BMD continued to increase at the hip and spine after 6, 18, and 30 months of treatment (Figure 4). The long-term effects of Testim have been evaluated in open-label extensions of two studies involving a total of 371 hypogonadal men\textsuperscript{30} receiving Testim 5 or 10 g daily for up to 12 months. Analysis of BMD showed that long-term treatment with Testim was associated with an increase in BMD that appeared incremental with longer duration of therapy.

Figure 3 Changes in body composition A) and muscle strength B) during treatment with Androgel. Reproduced with permission from Wang C, et al. J Clin Endocrinol Metab. 2004;89:2085–2098. © The Endocrine Society.
Long-term studies investigating the efficacy of testosterone gel therapy in reducing fracture risk are lacking.

**Sexual function**

Androgens have a role in several aspects of male sexual behavior such as libido, erectile function, and orgasms. Trials of testosterone gel replacement in hypogonadal men are consistent in showing an improvement in sexual function. In a one-month study designed specifically to explore the time to response in sexual activity after testosterone replacement, 638 hypogonadal men received 5 or 10 gm/d of Testim gel in an open-label fashion. After one week of Testim therapy, patients showed marked improvements in sexual function that continued to improve through week 2 and was maintained at week 4. Long-term studies using Androgel replacement in hypogonadal men (5 or 10 g/day) showed that sexual function (sexual desire, motivation, and sexual performance) increased in all treatment groups at 30 days and was maintained with continued use for three years. This and other data suggest that normalization of sexual function occurs once testosterone levels are restored to the lower adult male concentration range. Increasing serum testosterone levels to the upper normal range does not further improve sexual function. In a three-month study comparing 10 g Testim with Androderm and Andropatch, Steidle and colleagues treated 406 hypogonadal men. There was a significant improvement in mean scores for spontaneous erections, sexual desire, and performance in men on Testim compared to placebo. Improvements in sexual function and libido were also evident in another three-month study of 208 patients. Both doses of Testim (5 g/day and 10 g/d) produced improvements in spontaneous erections, sexual desire, and performance. Additionally, compared to Andropatch, treatment with Testim gel was associated with more consistent improvements in sexual motivation throughout the 90-day period, with significant differences from baseline at all time points. The benefits of Testim therapy on patients’ sexual function were also sustained over one year.

The benefit of testosterone gel as an adjunct therapy to sildenafil in men with erectile dysfunction (ED) was demonstrated in a study of 75 hypogonadal men with confirmed lack of response to sildenafil monotherapy. Testosterone-treated subjects had greater improvement in erectile function compared to those who received placebo, reaching statistical significance at week 4 ($P = 0.029$). Similar trends were observed for improvements in orgasmic function, overall satisfaction and International Index of Erectile Function (IIEF) score.

**Mood**

Studies have shown that testosterone levels correlate with mood. There is historic evidence of a strong positive correlation of testosterone with parameters such as mental well being, joyfulness, social interactivity, general arousal reaction, and wakefulness. Negative correlations have been reported with depression, nervousness, irritability, and anxiety.
In hypogonadal men receiving Androgel, positive mood parameters, such as sense of well being and energy level improved while negative parameters such as sadness and irritability decreased. The improvement in mood was observed on day 30 and was maintained with continued treatment for six[26] and 36 months. The improvement in mood parameters was not dependent on the magnitude of increase in serum testosterone levels. In fact, once serum testosterone increased into the low normal range, maximal improvement in mood parameters was seen. Thus, improvement in mood (similar to sexual function) in response to testosterone therapy appears to be dependent on reaching a threshold of serum testosterone that lies in the low normal range. The same results were replicated with the use of Testim where mood improved early after institution of treatment that was maintained for the duration of the treatment up to three months[27–29] and one year.[30] In a short-term study with Testim, Loizides and colleagues[34] showed that measures of positive and negative mood improved significantly, beginning with the first week of therapy and reaching a maximal response at the second week. Kuhnert and colleagues[38] have reported similar findings.

**Safety**

**Application site reactions**

The local tolerability of testosterone gel is superior to other transdermal products. In studies comparing testosterone gel with a testosterone patch, the incidence of adverse skin events has been significantly higher in the testosterone patch group. For instance, skin irritation was reported in 5.5% of subjects treated with Androgel and in 66% of subjects in the testosterone patch (Androderm) group in a six-month study of 227 hypogonadal men.[20]

The most commonly reported skin reactions were erythema and irritation at the application site. Upon longer follow up of approximately four years, skin irritation was minimal, did not appear to be dose dependant and was not a concerning cause for discontinuation.[26] Both short- and long-term studies using Testim also confirm these findings.[27,29,30]

**Prostate**

Long-term treatment with testosterone gel has shown a good safety profile with respect to the prostate. In the longest published trial of testosterone gel in which 163 hypogonadal men were treated for up to 42 months with Androgel,[26] the baseline mean prostate-specific antigen (PSA) level was 0.85 ± 0.06 ng/ml. Mean PSA at six months was 1.11 ± 0.08 ng/ml and showed no significant increase with continued testosterone treatment ($P = 0.150$). Furthermore, there was no difference in serum PSA levels among the three testosterone gel dose groups (5, 7.5, and 10 g/day). Mean international prostate symptom scores (IPPS) were not increased in subjects on gels. One subject had transurethral resection of the prostate for lower urinary tract symptoms. Of the subjects who had elevated PSA during the study, three had confirmed prostate cancer on biopsy (all $>60$ years old). In a long-term trial of Testim in 371 hypogonadal men (5 and 10 g/day),[30] baseline PSA concentrations were $1.26 ± 0.05$ ng/mL. The change from baseline were significant at each of the visits (0.39 ng/mL [month 3], 0.37 ng/mL [month 6], and 0.45 ng/mL [month 12]). In this study, three patients were diagnosed with prostate cancer. Two of them were aged 63 and 73 years and underwent biopsies because of rising PSA values. The third subject was 53 years old and had a biopsy 60 days post-treatment because of an asymmetrical prostate on digital exam. Mean IPSS scores were not increased from baseline. Although short-term studies[27,28,42] using Androgel or Testim have reported no cases of prostate cancer, one year[30] and three year[26] extensions of these studies have documented prostate cancer in a small number of subjects. In both short and long-term testosterone gel studies, PSA elevations of 4 ng/mL or greater have occurred only in a minority of individuals and many of them have either had normal PSA values on repeat measurements or normalization of PSA on discontinuation of testosterone or negative biopsies (in subjects who had persistent elevations in PSA despite treatment discontinuation).[26–28] Meikle and colleagues showed in a one-year study of physiological testosterone replacement in hypogonadal men that PSA levels remained within the normal range, and that none of the subjects developed benign prostatic hyperplasia during therapy.[38]

There is debate regarding cases of prostate cancer that are detected in trials involving long-term testosterone administration. Close monitoring of PSA in these trials, the heightened awareness of the investigators, and the rate of referral to a urologist for prostate biopsy be accountable for the increased detection of prostate cancer. There is also a concern that testosterone therapy may unmask asymptomatic occult prostate cancer. There still remains considerable uncertainty whether testosterone administration can lead to the growth and development of prostate cancer or if prostate cancer cases detected during therapy are coincidental to treatment.

**Hematocrit**

Increase in hematocrit (Hct) and hemoglobin (Hb) levels in clinical trials of testosterone replacement confirms the
decade-old known effects of testosterone on erythropoiesis. Long-term administration of 1% Androgel (5, 7.5, or 10 g/d) for 36 months showed that Hb and Hct levels increased steadily until month 12 in a dose-dependent manner with the 10 g/d group attaining the highest Hb and Hct concentrations. After 12 months there was no further increase in the levels. In the same study, 9% of men achieved Hb levels above 18 g/dl or Hct greater than 56% at some point during the study. In a 12-month study of 1% Testim in hypogonadal men, mean Hb and Hct values remained within the normal range. However, 2.4% of subjects showed an increased hematocrit beyond the acceptable range and were discontinued from the study. However, none of these studies examined if the response profile was significantly different in younger and older men.

**Skin transfer**

There is concern about the possibility of inadvertent interpersonal transfer of testosterone gel. In men, the bioavailability of applied testosterone gel is limited to 10%–15%. Upon application, testosterone penetrates the skin, with alcohol acting as a permeation enhancer. When applied to the skin, the alcohol evaporates quickly leaving significant amount of testosterone on the skin. Hence, a large reservoir of testosterone is left on the skin with the potential to be transferred. Unpublished studies from manufacturers indicate that both Androgel and Testim have the potential to raise testosterone levels in women after skin contact with treated men even hours after application. Additionally with abdominal application of Testim, wearing a shirt did not completely prevent the transfer of testosterone to the partner in spite of covering the area with a shirt. As of May 7th 2009, the US Food and Drug Administration (FDA) has instructed testosterone gel manufacturers to issue a “black box” warning regarding the potential for skin-to-skin transfer. This is a consequence of secondary exposure of children ranging in age from nine months to five years that were reported to the FDA. Adverse events reported in these children included enlargement of the genitalia, premature pubarche, advanced bone age, and aggressive behavior. Overall, covering the application site with clothing seems to minimize the risk of testosterone transfer during skin-to-skin contact. Even though there is paucity of cases reporting inter-personal transfer, the risk of transfer to women and children is possible. Hence, patient education is crucial.

**Monitoring treatment**

The goal of testosterone therapy should be to restore serum testosterone levels to the mid-normal range. In men receiving transdermal gel, testosterone level should be measured after patient has been on treatment for one to two weeks, ideally between two and six hours after gel application. Initial monitoring for symptom relief (improvement in libido, erectile function, energy and well being) should be performed three months after initiation of therapy. Failure to benefit from therapy within a reasonable time interval (3–6 months) should result in investigation for other causes of symptoms. A baseline BMD should be obtained in all hypogonadal men and repeated after one to two years of testosterone therapy to assess for interval changes in bone mass. Hematocrit should be measured at baseline, repeated at three months, and then annually. The Endocrine Society specifies a hematocrit cut-off of 54% above which testosterone therapy should be discontinued. If hematocrit rises above this level, testosterone therapy should be stopped until hematocrit decreases to a safe level. The patient should be evaluated for hypoxia and sleep apnea, and therapy should be restarted at a reduced dose. A therapeutic phlebotomy at periodic intervals may be required in some cases. Digital examination of the prostate and PSA measurement should be performed before initiating treatment, at three months, and annually thereafter depending upon the regional practice pattern. PSA increments of ≥1.4 ng/mL above baseline in any one-year period should warrant urologic evaluation and consideration of prostate biopsy. If longitudinal PSA data are available for more than two years, PSA velocity can be calculated to assess risk of prostate cancer. PSA velocity of more than 0.4 ng/ml/year, using the PSA level after six months of testosterone administration as the reference, requires further urological evaluation. PSA velocity should be used only if there are longitudinal PSA data for more than two years.

**Androgel versus Testim**

Although Androgel and Testim have well-established therapeutic efficacies, comparison studies that exist in the literature might prompt the provider to use one more than the other. Short-term, open-label studies have demonstrated that in patients who failed to respond to Androgel, their libido, erectile and ejaculatory function, cognition, and overall sexual satisfaction significantly improved following a switch to Testim. In a larger study, the records of 370 hypogonadal men on testosterone gel therapy (Testim or Androgel) were reviewed to identify men who underwent a brand substitution due to suboptimal response. Approximately 20% of these 370 men underwent brand substitution. Of these, 83% (n = 62) switched from Androgel to Testim. The predominant indication for gel substitution...
was either lack of improvement in symptoms or failure to achieve adequate serum levels. Following a change to Testim, mean total and free testosterone levels increased significantly (Figure 5) with only 17% of patients having total testosterone less than 300 ng/dL as compared to 58% while they were on Androgel. On the contrary, 17% of men (n = 13) switched from Testim to Androgel. The main indication for this substitution was the physical characteristics (scent and residue) of Testim. Following switch to Androgel, total testosterone levels remained below 300 ng/dL in 27% of these patients as compared to 15% while they were on Testim. These findings are probably explained by the differing pharmacokinetics of the two testosterone gels. The enhanced absorption of Testim is attributed to pentadecalactone, an emollient specific to Testim, which also accounts for the unique scent of the gel. In summary, although Testim appears to have a greater bioavailability than Androgel, this advantage is at the expense of undesirable physical properties such as its stickiness and smell. An easy option for Androgel users not achieving adequate serum testosterone levels would be to increase the dose rather than switching brands.

**Contraindications**

Baseline evaluation of hypogonadal men should include screening for conditions which could be exacerbated by testosterone therapy. Testosterone administration is contraindicated in men with prostate or breast cancer. Testosterone therapy should not be administered to men with a palpable prostate nodule (or induration), or if PSA is greater than 4 ng/mL (without a urological evaluation). Testosterone therapy should be administered carefully to men with benign prostatic hypertrophy and mild to moderate lower urinary tract symptoms. Men with severe lower urinary tract symptoms (IPSS symptom score >19) should undergo urological evaluation before consideration of testosterone therapy. Baseline assessment of prostate cancer risk is necessary in middle-aged and older men before instituting therapy. Age, race, family history of prostate cancer and PSA level – the major determinants of prostate cancer risk – should be factored in this risk assessment.

As testosterone therapy is expected to raise Hct, patients with baseline hematocrit >50% should not be given testosterone. Testosterone administration can cause salt and water retention and exacerbate edema in men with uncontrolled congestive heart failure. Therefore, testosterone should not be administered in men with class III or IV congestive heart failure. Men with moderate or severe obstructive sleep apnea should be evaluated by a sleep specialist before testosterone therapy is instituted.

**Conclusion**

The favorable pharmacokinetic profile and treatment outcomes combined with enhanced tolerability and superior compliance suggests that testosterone gel formulations are a safe and effective treatment in men with hypogonadism. Studies suggest that the two commercially available gels,
Androgel and Testim, are not bioequivalent and that Testim may have superior pharmacokinetic properties in comparison to Androgel. It appears that a brand substitution may be reasonable in nonresponders. While substitution from Androgel to Testim may result in higher testosterone levels and improved clinical responsiveness, a switch from Testim to Androgel may be needed in some subjects to eliminate the unwanted side effects related to the physical properties of the gel. However, it should be realized that trials comparing the efficacy of brand substitution to date have been unblinded. This methodological shortcoming compromises the quality of the findings as it is not known how much of an effect this bias would have on symptom amelioration.

The advantages of testosterone gel over the testosterone patch are a lower incidence of skin irritation, the ease of application, the invisibility of the gel, and the ability to deliver testosterone levels dose-dependently. Transdermal gel also gives stable testosterone levels while injectable testosterone esters are associated with “roller-coaster” pharmacokinetics where serum testosterone levels rise into the high normal or supraphysiological range immediately following injection, but fall into the hypogonadal range within two weeks. This is reflected in fluctuations in mood, energy, and sexual function. Injectable testosterone esters also result in a high incidence of polycythemia compared with gels due to higher circulating testosterone levels. Injectable testosterone undecanoate is a long-acting ester that maintains serum testosterone levels within the normal range without major fluctuations, and its longer half-life allows for administration every three months after an initial loading dose. This formulation is already in use in Europe and is awaiting FDA approval for use in the United States. However, a potential adverse effect of testosterone gel that should be borne in mind is the transfer risk to children and women upon close contact with the skin. Patient education is necessary.

**Disclosures**
The authors report no conflicts of interest in this work.

**References**
1. Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. *J Clin Endocrinol Metab*. 2004;89(12):5920–5926.
2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. *Baltimore Longitudinal Study of Aging*. *J Clin Endocrinol Metab*. 2001;86(2):724–731.
3. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. *J Clin Endocrinol Metab*. 2007;92(11):4241–4247.
4. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. *Endocr Pract*. 2002;8(6):440–456.
5. Blasi S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endorsement society clinical practice guideline. *J Clin Endocrinol Metab*. 2006;91(6):1995–2010.
6. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISSA, ISSAM, EAU, EAA and ASA recommendations. *Eur J Endocrinol*. 2008;159(5):507–514.
7. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab*. 2004;89(8):3813–3817.
8. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. *J Clin Endocrinol Metab*. 2004;89(8):3813–3817.
9. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab*. 1999;84(10):3666–3672.
10. Södergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol–17 beta to human plasma proteins at body temperature. *J Steroid Biochem*. 1982;16(6):801–810.
11. Rosner W, Aucius RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab*. Feb 7, 1992(2):405–413.
12. Simmer H, Arnold Adolph Berthold (1803–1861) Zur Erinnerung an den hundertsten Todestag des Begründers der experimentellen *Endokrinologie Dtsch med Wschr*. 1961;86:2186–2192.
13. Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP. Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. *Med J Aust*. 2002;177(11–12):678–679.
14. Vornoff S. *Testicular grafting from ape to man*. London, UK: Brentanos Ltd; 1920.
15. Nieschlag E, Behre HM, Nieschlag S. *Testosterone: Action, deficiency, substitution*. Cambridge, MA: Cambridge University Press; 2004. pp 14:405–406.
16. Junkmann K. Uber protrahiert wirksame androgene. *Arch Path Pharmacol*. 1952;215:85–92.
17. Niechlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. *Acta Endocrinol*. 1975;79:366–374.
18. Bals-Pratsch M, Knuth MA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. *Lancet*. 1986;2(8513):943–946.
19. Mazur NA, Heiber WE, Moellmer JF, et al. Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. *J Control Release*. 1992;19:347–362.
20. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. *J Clin Endocrinol Metab*. 2000;85(3):964–969.
21. Nieschlag E, Buecher D, Von Eckardstein S, Abshagen K, Simonni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. *Clin Endocrinol (Oxf)*. 1999;51(6):757–763.
22. Unimed-Pharmaceuticals Inc.; A Solvay Pharmaceuticals I, Company. *AndroGel prescribing information for healthcare professionals*. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2004.
23. Auxilium Pharmaceuticals I. *Testim prescribing information for healthcare professionals*. Norristown, PA: Auxilium Pharmaceuticals; 2004.
24. Sitruk-Ware R. Transdermal delivery of steroids. *Contraception*. 1989;39(1):1–20.
25. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab*. 2000;85(12):4500–4510.
26. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–2098.

27. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69–74.

28. Kuhnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol. 2005;153(2):317–326.

29. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673–2681.

30. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of androstenedione 1% testosterone gel in hypogonadal men. Rev Urol. 2004;6(Suppl 6):S22–S29.

31. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal gel formulation in hypogonadal men. J Sex Med. 2005;2(2):213–226.

32. Scott JD, Wolfe PR, Anderson P, Cohan GR, Scarsella A. Prospective study of topical testosterone gel (AndroGel) versus intramuscular administration to older men improves muscle function: molecular and functional evidence. J Androl. 2001;22(5):146–159.

33. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos. 2003;24(3):115–120.

34. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–159.

35. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147(1):141–154.

36. Brodsky IG, Balagopul P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3469–3475.

37. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282(3):E601–E607.

38. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Bone Miner Res. 1999;14(2):147–149.

39. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2008;159(6):E601–E607.

40. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and androgens inhibit interleukin-6 production by an androgen-sensitive human osteoblastic cell line. J Bone Miner Res. 1999;14(8):1330–1337.

41. Page ST, Herbst KL, Amory JK, et al. Testosterone administration normalizes interleukin-6 receptor expression in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males. Clin Cornerstone. 2005;7(Suppl 4):S20–S25.

42. Colvard DS, Eriksen EF, Keating PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989;86(3):854–857.

43. Pederson L, Kremer M, Judd J, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A. 1999;96(2):505–510.

44. Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEMS Lett. 2001;491(1–2):91–93.

45. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050–5055.

46. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–146.

47. Hofbauer LC, Ten RM, Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res. 1999;14(8):739–750.

48. Pilbeam CC, Raisz LG. Effects of androgens on parathyroid hormone and interleukin-1-stimulated prostaglandin production in cultured neonatal mouse calvariae. J Bone Miner Res. 1990;5(11):1183–1188.

49. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005;16(12):1487–1494.

50. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001;54(6):739–750.

51. Nieschlag E, Behre HM. Testosterone: Action, Deficiency, Substitution. Cambridge, MA: Cambridge University Press; 2004.

52. Loizides E, Swierzewski MJ, O’Neill C, Griesser J, Smith T. Early response time in sexual activity and mood following testosterone gel replacement in hypogonadal males from the Testim(R) START Study. Rev Urol. 2004;6(Suppl 6):S16–S21.

53. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181.

54. Sefel AD, Mack RJ, Secret AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004;25(6):963–972.

55. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2008;179(5 Suppl):S97–S102.

56. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49(2):191–196.

57. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod. 2009;24(2):425–428.

58. Food and Drug Administration. Testosterone gel safety concerns prompt FDA to require label changes, medication guide. Available from: http://www.fda.gov/bbs/topics/NEWS/2009/NEW02011.html.

59. Groder ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213–217.

60. Nieschlag E, Coppers HW, Wiegell WM, Wickers EH. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res. 1976;7(3):138–145.

61. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51(6):1335–1339.
65. Partsch CJ, Weinbauer GF, Fang R, Nieschlag E. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. *Eur J Endocrinol*. 1995;132(4):514–519.

66. Schubert M, Minnemann T, Hubler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. *J Clin Endocrinol Metab*. 2004;89(11):5429–5434.

67. Minnemann T, Schubert M, Freude S, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. *J Endocrinol Invest*. 2008;31(8):718–723.